Head and Neck Cancer - Drug Pipeline Analysis and Market Forecasts to 2016
Posted Apr 19 2010 4:10am
The industry analysis specialist, has released its new report, “Head and Neck Cancer - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global head and neck cancer market. The report identifies the key trends shaping and driving the global head and neck cancer market. It also provides insights on the current competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. More importantly, the report gives valuable insights on the pipeline products within the global head and neck cancer sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts. Estimated the global head and neck cancer market to be valued at $1,035m in 2009. It is forecast to grow by 8.3% annually for the next seven years to reach $1,809m by 2016. This growth is primarily attributed to the high incidence rate, prevalence rate and diagnosis rate of the disease and the high prescription rates of the currently approved products, as well as the development of vaccines, gene therapy and biologics across different stages of clinical trials. It has concluded that the global head and neck cancer market is moderately served with the current product options and there is significant scope available to new entrants to capture value from underserved segments. Designing a product which can improve the five-year survival rate, reduce tumor size, prevent tumor recurrence and offer a high safety profile is one of key challenges for prospective entrants to this market and could provide a significant market share for any company. It found that the global head and neck cancer market is becoming increasingly competitive. The unmet need in the head and neck cancer market is high and if a company wants to capture this unmet need, it will need to improve on the prevailing products’ weaknesses and adverse effects.
The scope of the report includes:
Annualized global head and neck cancer market revenues data from 2001 to 2009, forecast forward 7 years to 2016.
Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include growth factor receptors, kinase targetters, drugs that target DNA, RNA and their synthesis, vaccines, gene therapies, histone deacetylase inhibitors, therapies based on cytokines and combination therapies.
Analysis of the current and future market competition in the global head and neck cancer market. The key market players covered are Oncolytics Biotech Inc, Biovex Limited, Ym Biosciences Inc. and GlaxoSmithKline.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the future head and neck caner market.